|
|
News Breaks
|
November 3, 2009
|
| 18:05 EDT |  | MNOV |
| theflyonthewall.com: | MedicNova initiates Phase Ib clinical trial for MN-221 | | MediciNova and the Hercules Market of the Osaka Securities Exchange announced the initiation of a Phase Ib clinical trial, by holding the Investigator's Meeting, to evaluate the safety of MN-221 at planned escalating doses in patients with stable, moderate to severe chronic obstructive pulmonary disease. COPD exacerbations represents the second respiratory indication for which MediciNova is currently evaluating MN-221. :theflyonthewall.com |
|
|
News For MNOV From The Last 14 Days Check below for free stories on MNOV the last two weeks.
There are 4 items on the Fly with pertinent information.
Sign up for a free trial to see the rest of the stories you've been missing. |
|
February 3, 2012
|
| 12:00 EDT |  | MNOV |
|
|
February 2, 2012
|
| 12:00 EDT | | MNOV |
| | 10:00 EDT | | MNOV |
| theflyonthewall.com: | MedicNova rises 29.6% | | MedicNova is up 29.6%, or 56c, to $2.45 :theflyonthewall.com |
|
|
February 1, 2012
|
| 06:31 EDT | | MNOV |
| theflyonthewall.com: | MedicNova receives notice of patent allowance for a method of treating MS | | MediciNova Inc, a biopharmaceutical company traded on the NASDAQ Global Market and the Jasdaq Market of the Osaka Securities Exchange (4875), announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for a pending patent application, which covers the use of ibudilast for the treatment of progressive forms of multiple sclerosis. Ibudilast (MN-166), is the company's lead drug development candidate for certain neurological conditions, including progressive multiple sclerosis, neuropathic pain, and drug addiction. :theflyonthewall.com |
|
|
|
|
|
Subscribe for More Information